---
title: "Vivimed Labs Ltd (VIVIMEDLAB) — Share Price, Financials & Analysis"
symbol: "VIVIMEDLAB"
company: "Vivimed Labs Ltd"
canonical: "https://tapetide.com/stocks/VIVIMEDLAB"
isin: "INE526G01021"
nse_symbol: "VIVIMEDLAB"
bse_code: "532660"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 50
generated_at: "2026-09-13T18:56:17.914Z"
---

# Vivimed Labs Ltd (VIVIMEDLAB)

Canonical page: https://tapetide.com/stocks/VIVIMEDLAB

## Company

- **NSE Symbol:** VIVIMEDLAB
- **BSE Code:** 532660
- **ISIN:** INE526G01021
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2005-08-17
- **CEO:** Dr. Manohar Rao Varalwar
- **Employees:** 586
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** vivimedlabs.com

## About

Vivimed Labs Ltd, established in 1988,  is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.[1][2]

## Latest Price

- **Price:** ₹6.03
- **Change:** -0.12 (-1.95%)
- **Open:** ₹6.03
- **Day High:** ₹6.03
- **Day Low:** ₹6.03
- **Previous Close:** ₹6.15
- **Volume:** 21885
- **As Of:** 2026-09-11T09:14:36+00:00

## Key Fundamentals

Observed at 2026-09-11T04:51:48.332697Z.

- **Market Cap:** ₹50 Cr
- **Classification:** Microcap
- **P/E (reported):** -0.3
- **EPS (TTM):** ₹-21.28
- **Book Value:** ₹-29.98
- **Price to Book:** -0.21
- **Dividend Yield:** 0%
- **ROE:** 90.88%
- **ROCE:** -5.64%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹69.99 Cr
- **Net Income:** ₹-176.42 Cr
- **EBITDA:** ₹-152.43 Cr
- **52-Week High:** ₹29.4
- **52-Week Low:** ₹4.75
- **RSI (14):** 50.29

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -39.5% over past five years.
- Promoter holding is low: 7.57%
- Contingent liabilities of Rs.183 Cr.
- Company has high debtors of 236 days.
- Promoter holding has decreased over last 3 years: -13.4%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 92.71% | -104.95% | -100.31% |
| net income growth | -791.52% | 451.31% | 14% | 160.59% |
| revenue growth | 11.25% | -41.97% | -28% | -39% |
| roce | 839.16% | -29.76% | -89.07% | -13.96% |
| roe | 788.94% | -89.08% | 29.9% | -645.5% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 35 | 34 | 41 | 39 | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| Expenses | 36 | 40 | 40 | 67 | 40 | 25 | 35 | 28 | 22 | 22 | 27 | 152 |
| Operating Profit | 0 | -6 | 1 | -28 | -11 | -1 | 1 | -2 | 0 | -1 | -11 | -140 |
| OPM % | -0.9 | -18 | 3.1 | -74 | -37 | -2.6 | 2.9 | -10 | -1.3 | -4.6 | -68 | -1169 |
| Other Income | 0 | 2 | 0 | 8 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 6 |
| Interest | 11 | 12 | 13 | -33 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 5 | 5 | 5 | 6 | 4 | 4 | 7 | 6 | 5 | 5 | 5 | 12 |
| Profit before tax | -16 | -20 | -17 | 7 | -15 | -5 | -6 | -5 | -5 | -7 | -17 | -147 |
| Tax % | 0 | 0 | -3 | 21 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Net Profit | -16 | -20 | -16 | 5 | -15 | -5 | -6 | -6 | -5 | -7 | -17 | -147 |
| EPS in Rs | -1.88 | -2.45 | -1.94 | 0.63 | -1.84 | -0.62 | -0.72 | -0.68 | -0.66 | -0.88 | -2 | -17.74 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1462 | 1186 | 1315 | 1059 | 861 | 237 | 187 | 149 | 116 | 70 |
| Expenses | 1057 | 971 | 1135 | 1049 | 830 | 245 | 374 | 182 | 129 | 222 |
| Operating Profit | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -33 | -13 | -152 |
| OPM % | 28 | 18 | 14 | 1 | 3.7 | -3.3 | -100 | -22 | -11 | -218 |
| Other Income | 8 | 10 | 23 | 8 | 10 | 1 | 1 | 10 | 4 | 6 |
| Interest | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 3 | 3 | 4 |
| Depreciation | 58 | 56 | 67 | 67 | 56 | 18 | 108 | 20 | 20 | 26 |
| Profit before tax | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -46 | -32 | -176 |
| Tax % | 25 | 11 | 13 | 0 | 3 | 4 | -1 | -1 | 0 | 0 |
| Net Profit | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 | -176 |
| EPS in Rs | 26.41 | 9.44 | 6.95 | -13.16 | -8.67 | -8.16 | -39.62 | -5.48 | -3.85 | -21.28 |
| Dividend Payout % | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 718 | 885 | 602 | 493 | 415 | 348 | 23 | -22 | -52 | -227 |
| Borrowings | 1011 | 1149 | 1280 | 1268 | 326 | 359 | 379 | 377 | 376 | 397 |
| Other Liabilities | 317 | 343 | 431 | 432 | 532 | 543 | 658 | 579 | 580 | 567 |
| Total Liabilities | 2062 | 2394 | 2329 | 2210 | 1289 | 1266 | 1076 | 950 | 921 | 753 |
| Fixed Assets | 879 | 1035 | 965 | 1045 | 502 | 520 | 436 | 418 | 408 | 386 |
| CWIP | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 | 17 | 18 |
| Investments | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 168 | 168 | 181 |
| Other Assets | 1104 | 1290 | 1239 | 990 | 529 | 507 | 421 | 343 | 328 | 170 |
| Total Assets | 2062 | 2394 | 2329 | 2210 | 1289 | 1266 | 1076 | 950 | 921 | 753 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 58 | 21 | 422 | 80 | 567 | 28 | 35 | -24 | -2 | 8 |
| Cash from Investing Activity | -68 | -164 | -89 | -196 | 404 | -16 | -5 | 28 | -5 | -1 |
| Cash from Financing Activity | 35 | 186 | -338 | 72 | -1015 | -10 | -34 | -6 | 5 | -6 |
| Net Cash Flow | 25 | 44 | -5 | -44 | -44 | 1 | -3 | -2 | -1 | 1 |
| Free Cash Flow | -11 | -142 | 333 | -33 | 1084 | 11 | 30 | -26 | -6 | 7 |
| CFO/OP | 23 | 30 | 243 | 972 | 1720 | -352 | -19 | 73 | 13 | -5 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 50 | 85 | 99 | 86 | 46 | 134 | 145 | 203 | 233 | 236 |
| Inventory Days | 329 | 411 | 397 | 396 | 263 | 573 | 216 | 327 | 358 | 63 |
| Days Payable | 122 | 154 | 207 | 179 | 35 | 100 | 74 | 225 | 240 | 263 |
| Cash Conversion Cycle | 258 | 342 | 288 | 303 | 274 | 607 | 286 | 305 | 351 | 36 |
| Working Capital Days | 55 | 121 | 68 | 216 | 77 | 195 | -15 | -171 | -255 | -1468 |
| ROCE % | 22 | 9 | 7 | -3 | -1 | -3 | -52 | -11 | -8 | -65 |

## Shareholding Pattern

### Quarterly

| Category | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 20.94% | 20.94% | 20.94% | 20.94% | 20.94% | 20.94% | 20.94% | 20.94% | 7.77% | 7.77% | 7.77% | 7.57% |
| FIIs | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% |
| Public | 57% | 56.71% | 56.7% | 57.24% | 57.23% | 57.23% | 57.3% | 57.91% | 65.19% | 65.18% | 65.06% | 68.75% |
| Others | 20.3% | 20.59% | 20.6% | 20.07% | 20.07% | 20.07% | 20% | 19.39% | 25.29% | 25.3% | 25.41% | 21.91% |
| No. of Shareholders | 49503 | 49038 | 49027 | 49016 | 49012 | 49003 | 49005 | 48957 | 48928 | 48925 | 49221 | 47492 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 8 / 2 / 9

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 6.47 | Sell |
| EMA (10) | 6.33 | Sell |
| SMA (20) | 6.36 | Sell |
| EMA (20) | 6.23 | Sell |
| SMA (50) | 5.66 | Buy |
| EMA (50) | 5.99 | Buy |
| SMA (100) | 6.02 | Buy |
| EMA (100) | 6.21 | Sell |
| SMA (200) | 7.35 | Sell |
| EMA (200) | 7.04 | Sell |

### Oscillators — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 46.98 | Neutral |
| MACD (12,26,9) | 0.19 | Sell |
| Stochastic (14,3,3) | 2.31 | Buy |
| ADX (14) | 29.18 | Buy |
| Williams %R (14) | -100 | Buy |
| ATR (14) | 0.21 | High Volatility |
| ROC (12) | -11.45 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 28.68 | Buy |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=de7cdbe5-819b-495e-8d28-4411f988ef8b.pdf) |
| 2026-08-17 | [Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb4c4760-ce82-4a94-83aa-ddffba62d339.pdf) |
| 2026-07-22 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ed9315b-25d5-423d-8a96-43498075e323.pdf) |
| 2026-07-22 | [Re- Lodgement Of Transfer Requests](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7b48119-81e3-4faa-b560-bcdc3d06073a.pdf) |
| 2026-07-14 | [Board Meeting Intimation for Quarter & Year End Results 31.3.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5cf22371-89af-4ccc-8732-d415dd939732.pdf) |
| 2026-07-10 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cee3154a-6af8-4ac5-969c-558af7e072cc.pdf) |
| 2026-06-30 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d900f9a-f673-4e2c-9c10-39762960e387.pdf) |
| 2026-06-17 | [Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0249ddf9-f406-42db-9697-52757ba6faa9.pdf) |
| 2026-05-30 | [Board Meeting Postponed](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eba5ac11-7bb7-44fc-b33f-09999e6e2d80.pdf) |
| 2026-05-26 | [Update on board meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4eb20d66-8ae6-45fa-85a1-c7967d8e52f9.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-17 | [Results As On 31.3.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=91373088-245b-4364-b263-5b01936209ba.pdf) |
| 2026-03-13 | [Q3 FY 2026 RESULTS](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70ae77fe-3b0a-49da-add1-65d21574dba1.pdf) |
| 2025-11-13 | [Results H1 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be62f17d-2494-442d-9aa9-9bef0cdb13eb.pdf) |
| 2025-11-13 | [Revised Results H1 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee0634e5-8fd0-42c1-908f-57986b3edbab.pdf) |
| 2025-08-13 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92488773-6e8e-45ed-a2f2-3c892d1d16c8.pdf) |
| 2025-05-31 | [Results FY2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa1e7178-75df-4a8f-8b6f-5dad2810c92e.pdf) |
| 2025-02-14 | [Q3 Results FY2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38c02434-e6e8-4e87-9c7f-5ab3cdb0ca31.pdf) |
| 2025-01-11 | [Resultsq1fy2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4622b1b1-5ae6-4b02-bd00-6139b589b8c5.pdf) |
| 2025-01-11 | [Resultsh1fy2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab34c3dd-aefe-4e9e-8289-8dd965b4b081.pdf) |
| 2024-11-14 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2cffa3b6-7d28-4558-92ba-5354967ddf25.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Board meeting on 13 Mar 2026 to approve unaudited Q3/9M results ending 31 Dec 2025. | [Board Meeting Intimation for Notice Of Board Meeting 9 Mar - Board meeting on 13 Mar 2026 to approve unaudited Q3/9M results ending 31 Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/28ff3874-20dd-4aec-b338-d8a6f3fa8a05.pdf) |
| 9 Feb - CBI searched Vivimed on Jan 20; High Court granted interim stay on Feb 6, 2026 against coercive action. | [Disclosure Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015 (Listing Regulations) 9 Feb - CBI searched Vivimed on Jan 20; High Court granted interim stay on Feb 6, 2026 against coercive action.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3f5b3826-0551-4bd3-a7eb-2a13a0282a02.pdf) |
| 8 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/76a0e128-01e6-451b-9cff-84e6bdfa6b6b.pdf) |
| 6 Apr - Vivimed Labs declares it is outside the SEBI large corporate entity framework. | [Initial Disclosure 6 Apr - Vivimed Labs declares it is outside the SEBI large corporate entity framework.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ab7f4900-43b5-4bb6-b968-2856399d9562.pdf) |
| 23 Apr - NCLT Bengaluru started CIRP for Vivimed Labs on 15.04.2026; claims due by 01.05.2026. | [Corporate Insolvency Resolution Process (CIRP)-Public Announcement 23 Apr - NCLT Bengaluru started CIRP for Vivimed Labs on 15.04.2026; claims due by 01.05.2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fa5c6d05-6797-4503-83fe-5b78e278b191.pdf) |
| 17 Apr - Vivimed Labs admitted to CIRP by NCLT Bengaluru; moratorium imposed and IRP appointed. | [Admission To CIRP 17 Apr - Vivimed Labs admitted to CIRP by NCLT Bengaluru; moratorium imposed and IRP appointed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cd870e56-e39e-4bf5-97e6-8c1ce1b29c0a.pdf) |
| 16 Feb - CBI case (RC 03(E)/2025) registered Nov 19, 2025; High Court granted interim stay on Feb 6, 2026. | [Updates 16 Feb - CBI case (RC 03(E)/2025) registered Nov 19, 2025; High Court granted interim stay on Feb 6, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cfb9509b-f09f-47f6-9dd5-097c97091566.pdf) |
| 14h - NCLT Bengaluru started CIRP for Vivimed Labs on 15.04.2026; claims due by 01.05.2026. | [Corporate Insolvency Resolution Process (CIRP)-Public Announcement 14h - NCLT Bengaluru started CIRP for Vivimed Labs on 15.04.2026; claims due by 01.05.2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/fa5c6d05-6797-4503-83fe-5b78e278b191.pdf) |
| 13 Mar - Board approved unaudited Q3 & 9M results to 31/12/2025; auditor qualified—unaccrued interest Rs164.52m(Q)/Rs472.37m(YTD), provision Rs46.03m. | [Q3 FY 2026 RESULTS 13 Mar - Board approved unaudited Q3 & 9M results to 31/12/2025; auditor qualified—unaccrued interest Rs164.52m(Q)/Rs472.37m(YTD), provision Rs46.03m.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/70ae77fe-3b0a-49da-add1-65d21574dba1.pdf) |
| 13 Feb - Vivimed filed PPIRP application with NCLT Bengaluru on 12 Feb 2026; default Rs.512.53 crore as of 31 Jan 2026. | [Application For PPIRP 13 Feb - Vivimed filed PPIRP application with NCLT Bengaluru on 12 Feb 2026; default Rs.512.53 crore as of 31 Jan 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/14f750ca-6e8d-4699-996f-f3b5f101c819.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2011 from nse](https://archives.nseindia.com/annual_reports/AR_VIVIMEDLAB_2010_2011_25102011045556.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/aa651044-9ab8-4f61-b862-65b6ac46ff36.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/72158708-206c-4dd4-bcbe-7d272e62b093.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fceb4bc2-4e76-4188-a4f5-388c7b8c7642.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e6bf2a2d-73df-4a04-b8e9-d3be8d75d6ac.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0ccc72f2-3c86-481d-8359-a0f01961a3e4.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/532660/68106532660.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/532660/5326600319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/532660/5326600318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/532660/5326600317.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2018 | [Concall - Nov 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66647ad4-f109-4f8c-ba5f-61c6acdca045.pdf) |
| Nov 2018 | [Concall - Nov 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/11/66647ad4-f109-4f8c-ba5f-61c6acdca045.pdf) |
| Nov 2017 | [Concall - Nov 2017](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8308cdfb-8aa6-49fa-a5de-42f1da98abf2.pdf) |
| Nov 2017 | [Concall - Nov 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/11/8308cdfb-8aa6-49fa-a5de-42f1da98abf2.pdf) |
| Mar 2019 | [Concall - Mar 2019](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3fc8dc06-1077-4ee9-8707-4d59f40674df.pdf) |
| Mar 2019 | [Concall - Mar 2019](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3fc8dc06-1077-4ee9-8707-4d59f40674df.pdf) |
| Jun 2018 | [Concall - Jun 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4cb9b4a-0887-4be8-95f0-a7ea14ae823d.pdf) |
| Jun 2018 | [Concall - Jun 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/6/f4cb9b4a-0887-4be8-95f0-a7ea14ae823d.pdf) |
| Feb 2018 | [Concall - Feb 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3296e6da-cb6c-4e4d-9d6f-e2a2f201dee2.pdf) |
| Feb 2018 | [Concall - Feb 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/2/3296e6da-cb6c-4e4d-9d6f-e2a2f201dee2.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:56:17.914Z.